{"id":14597,"date":"2012-02-17T00:30:00","date_gmt":"2012-02-16T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/teva-profitti-a-23-nel-4-trimestre-2011\/"},"modified":"2012-02-17T00:30:00","modified_gmt":"2012-02-16T23:30:00","slug":"teva-profitti-a-23-nel-4-trimestre-2011","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/teva-profitti-a-23-nel-4-trimestre-2011\/","title":{"rendered":"Teva: Profits up +23% in Q4 2011"},"content":{"rendered":"<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span style=\"line-height: 115%; font-size: 14pt\"><font face=\"Calibri\"><font size=\"5\"><\/font><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\" align=\"center\"><span style=\"line-height: 115%; font-size: 14pt\"><font face=\"Calibri\"><font size=\"5\"><img loading=\"lazy\" decoding=\"async\" style=\"width: 307px; height: 97px\" id=\"rg_hi\" class=\"rg_hi\" alt=\"\" width=\"400\" height=\"126\" data-height=\"126\" data-width=\"400\" src=\"http:\/\/t3.gstatic.com\/images?q=tbn:ANd9GcQX4IVb0hM8isRl2bKbRulS6ITlJLf6QqScoa6zT3FSCsoIFOPqWA\" \/><\/font><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span style=\"line-height: 115%; font-size: 14pt\"><font face=\"Calibri\"><font size=\"5\"><\/font><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><span style=\"line-height: 115%; font-size: 14pt\"><font face=\"Calibri\"><font size=\"5\">In the fourth quarter of 2011, the profit of the Israeli Teva, a global producer of generic drugs, rose by 23% to 1.4 billion dollars. The increase in profits was driven by contributions from US-based Cephalon, a biotech company specializing in drugs for the central nervous system, pain and oncology, acquired in 2011.<\/p>\n<p><\/font><\/font><\/span><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><em style=\"mso-bidi-font-style: normal\"><span style=\"line-height: 115%; font-size: 9pt\"><font face=\"Calibri\">(Il Sole 24 Ore Pag.30 \u2013 16\/02\/2012)<span style=\"mso-spacerun: yes\">&nbsp; <\/span><\/font><\/span><\/em><\/p>\n<p style=\"margin: 0cm 0cm 10pt\" class=\"MsoNormal\"><em style=\"mso-bidi-font-style: normal\"><span style=\"line-height: 115%; font-size: 9pt\"><font face=\"Calibri\"><\/font><\/p>\n<p><img","protected":false},"excerpt":{"rendered":"<p>L&#8217;utile dell&rsquo;israeliana Teva, produttore mondiale di farmaci generici, nel quarto trimestre del 2011 &egrave; salito del 23% a 1,4 mld di dollari. L&#8217;incremento dei profitti &egrave; stato favorito dai contributi della statunitense Cephalon, societ&agrave; biotech specializzata nei farmaci per il Sistema nervoso centrale, il dolore e l&rsquo;oncologia, acquisita nel 2011. (Il Sole 24 Ore Pag.30 &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-14597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=14597"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/14597\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=14597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=14597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=14597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}